Acumen price target lowered to $11 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Acumen (ABOS) to $11 from $15 and keeps a Buy rating on the shares. The firm says completion of enrollment of the ALTITUDE AD trial “indicates an overall enthusiasm for a differentiated anti Abeta immunotherapy despite the availability of two drugs in the market.” However, as investors await topline data which might be disclosed around the end of 2026, the Alzheimer’s disease therapeutic landscape might see approval of plasma biomarkers sometime this year, the analyst tells investors in a research note. H.C. Wainwright reduced Acumen’s price target to reflect new spending assumptions going forward.